Brigham and Women's Hospital Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Eur J Clin Invest. 2012 Aug;42(8):900-13. doi: 10.1111/j.1365-2362.2012.02667.x. Epub 2012 Mar 21.
Chronic lung diseases contribute significantly to the morbidity and mortality of the population. There are few effective treatments for many chronic lung diseases, and even fewer therapies that can arrest or reverse the progress of the disease.
In this review, we present the current state of regenerative therapies for the treatment of chronic lung diseases. We focus on endothelial progenitor cells, mesenchymal stem cells, and endogenous lung stem/progenitor cells; summarize the work to date in models of lung diseases for each of these therapies; and consider their potential benefits and risks as viable therapies for patients with lung diseases.
Cell-based regenerative therapies for lung diseases offer great promise, with preclinical studies suggesting that the next decade should provide the evidence necessary for their ultimate application to our therapeutic armamentarium.
慢性肺部疾病是导致人群发病率和死亡率的主要原因。对于许多慢性肺部疾病，目前几乎没有有效的治疗方法，能够阻止或逆转疾病进展的疗法更是少之又少。
在这篇综述中，我们介绍了治疗慢性肺部疾病的再生疗法的最新进展。我们重点介绍内皮祖细胞、间充质干细胞和内源性肺干细胞/祖细胞；总结了目前为止针对这些疗法的肺部疾病模型中的工作；并考虑了它们作为肺部疾病患者可行治疗方法的潜在益处和风险。
基于细胞的肺部疾病再生疗法前景广阔，临床前研究表明，未来十年应该提供必要的证据，最终将其应用于我们的治疗武器库中。
